Generics can’t stop heart drug cartel suit

A federal judge in New York held last week that indirect and direct purchasers had sufficiently alleged that several generic drugmakers orchestrated a scheme to fix and raise the price of propranolol hydrochloride.

Get unlimited access to all Global Competition Review content